Interferon-λ1 Linked to a Stabilized Dimer of Fab Potently Enhances both Antitumor and Antiviral Activities in Targeted Cells

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Liu, Donglin ^a   Chang, Chien Hsing ^a,b   Rossi, Edmund A ^a   Cardillo, Thomas M ^b   Goldenberg, David M ^a,b,c  

^a IBC Pharmaceuticals Inc   (United States)

^b IMMUNOMEDICS INC   (United States)

^c CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; CYTOKINE; DIMER; EPIDERMAL GROWTH FACTOR RECEPTOR; HLA DR ANTIGEN; IMMUNOGLOBULIN F(AB) FRAGMENT; INTERLEUKIN 28; INTERLEUKIN 29; PEGINTERFERON ALPHA2B;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN BINDING; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG POTENCY; ENCEPHALOMYOCARDITIS VIRUS; FEMALE; HEPATITIS C VIRUS; IMMUNOMODULATION; LUNG ADENOCARCINOMA; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PURIFICATION;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENCEPHALOMYOCARDITIS VIRUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HEPACIVIRUS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INTERFERONS; MICE; MICE, NUDE;

EID: 84877814739     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0063940     Document Type: Article

References (49)

1. Pestka S, Krause CD, Walter MR, (2004) Interferons, interferon-like cytokines, and their receptors. Immunol Rev 202: 8-32.
2. George PM, Badiger R, Alazawi W, Foster GR, Mitchell JA, (2012) Pharmacology and therapeutic potential of interferons. Pharmacol Ther 135: 44-53.
3. Ferrantini M, Capone I, Belardelli F, (2007) Interferon-α and cancer: mechanisms of action and new perspectives of clinical use. Biochimie 89: 884-893.
4. Miller DM, Klucher KM, Freeman JA, Hausman DF, Fontana D, et al. (2009) Interferon lambda as a potential new therapeutic for hepatitis C. Ann N Y Acad Sci. 1182: 80-87.
5. Trinchieri G, (2010) Type I interferon: friend or foe? J Exp Med 207: 2053-2063.
6. Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, et al. (2003) IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 4: 69-77.
7. Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, et al. (2003) IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 4: 63-68.
8. Witte K, Witte E, Sabat R, Wolk K, (2010) IL-28A, IL-28B, and IL-29: promising cytokines with type I interferon-like properties. Cytokine Growth Factor Rev 21: 237-251.
9. Zhou Z, Hamming OJ, Ank N, Paludan SR, Nielsen AL, et al. (2007) Type III interferon (IFN) induces a type I IFN-like response in a restricted subset of cells through signaling pathways involving both the Jak-STAT pathway and the mitogen-activated protein kinases. J Virol 81: 7749-7758.
10. Pestka S, (2007) The interferons: 50 years after their discovery, there is much more to learn. J Biol Chem 282: 20047-20051.
11. Wolk K, Witte E, Reineke U, Witte K, Friedrich M, et al. (2005) Is there an interaction between interleukin-10 and interleukin-22? Genes Immun 6: 8-18.
12. Witte K, Gruetz G, Volk HD, Looman AC, Asadullah K, et al. (2009) Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines. Genes Immun 10: 702-714.
13. Ank N, West H, Bartholdy C, Eriksson K, Thomsen AR, et al. (2006) Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J Virol 80: 4501-4509.
14. Robek MD, Boyd BS, Chisari FV, (2005) Lambda interferon inhibits hepatitis B and C virus replication. J Virol 79: 3851-3854.
15. Doyle SE, Schreckhise H, Khuu-Duong K, Henderson K, Rosler R, et al. (2006) Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. Hepatology 44: 896-906.
16. Ank N, Iversen MB, Bartholdy C, Staeheli P, Hartmann R, et al. (2008) An important role for type III interferon (IFN-lambda/IL-28) in TLR-induced antiviral activity. J Immunol 180: 2474-2485.
17. Marcello T, Grakoui A, Barba-Spaeth G, Machlin ES, Kotenko SV, et al. (2006) Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 131: 1887-1898.
18. Pagliaccetti NE, Eduardo R, Kleinstein SH, Mu XJ, Bandi P, et al. (2008) Interleukin-29 functions cooperatively with interferon to induce antiviral gene expression and inhibit hepatitis C virus replication. J Biol Chem 283: 30079-30089.
19. Jewell NA, Cline T, Mertz SE, Smirnov SV, Flano E, et al. (2010) Lambda interferon is the predominant interferon induced by influenza A virus infection in vivo. J Virol 84: 11515-11522.
20. Pott J, Mahlakoiv T, Mordstein M, Duerr CU, Michiels T, et al. (2011) IFN-lambda determines the intestinal epithelial antiviral host defense. Proc Natl Acad Sci U S A 108: 7944-7949.
21. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, et al. (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461: 399-401.
22. Hsu CS, Hsu SJ, Chen HC, Tseng TC, Liu CH, et al. (2011) Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy. Proc Natl Acad Sci U S A 108: 3719-3724.
23. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, et al. (2009) Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461: 798-801.
24. Dellgren C, Gad HH, Hamming OJ, Melchjorsen J, Hartmann R, (2009) Human interferon-lambda3 is a potent member of the type III interferon family. Genes Immun 10: 125-131.
25. Zitzmann K, Brand S, Baehs S, Goke B, Meinecke J, et al. (2006) Novel interferon-lambdas induce antiproliferative effects in neuroendocrine tumor cells. Biochem Biophys Res Commun 344: 1334-1341.
26. Meager A, Visvalingam K, Dilger P, Bryan D, Wadhwa M, (2005) Biological activity of interleukins-28 and-29: comparison with type I interferons. Cytokine 31: 109-118.
27. Maher SG, Sheikh F, Scarzello AJ, Romero-Weaver AL, Baker DP, et al. (2008) IFNalpha and IFNlambda differ in their antiproliferative effects and duration of JAK/STAT signaling activity. Cancer Biol Ther 7: 1109-1115.
28. Guenterberg KD, Grignol VP, Raig ET, Zimmerer JM, Chan AN, et al. (2010) Interleukin-29 binds to melanoma cells inducing Jak-STAT signal transduction and apoptosis. Mol Cancer Ther 9: 510-520.
29. Li Q, Kawamura K, Ma G, Iwata F, Numasaki M, et al. (2010) Interferon-lambda induces G1 phase arrest or apoptosis in oesophageal carcinoma cells and produces anti-tumour effects in combination with anti-cancer agents. Eur J Cancer 46: 180-190.
30. Numasaki M, Tagawa M, Iwata F, Suzuki T, Nakamura A, et al. (2007) IL-28 elicits antitumor responses against murine fibrosarcoma. J Immunol 178: 5086-5098.
31. Sato A, Ohtsuki M, Hata M, Kobayashi E, Murakami T, (2006) Antitumor activity of IFN-lambda in murine tumor models. J Immunol 176: 7686-7694.
32. Muir AJ, Shiffman ML, Zaman A, Yoffe B, de la Torre A, et al. (2010) Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology 52: 822-832.
33. Ramos EL, (2010) Preclinical and clinical development of pegylated interferon-lambda 1 in chronic hepatitis C. J Interferon Cytokine Res. 30: 591-595.
34. Zeuzem S, Arora S, Bacon B, Box T, Charlton M, et al. (2011) Pegylated interferon-lambda (pegifn-λ) shows superior viral response with improved safety and tolerability versus pegifnα-2a in hcv patients (gl/2/3/4): emerge phase iib through week 12. Journal of Hepatology 54: S538-S539.
35. Chang CH, Rossi EA, Goldenberg DM, (2007) The dock and lock method: a novel platform technology for building multivalent, multifunctional structures of defined composition with retained bioactivity. Clin Cancer Res 13: 5586s-5591s.
36. Rossi EA, Goldenberg DM, Cardillo TM, McBride WJ, Sharkey RM, et al. (2006) Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting. Proc Natl Acad Sci U S A 103: 6841-6846.
37. Rossi EA, Goldenberg DM, Cardillo TM, Stein R, Chang CH, (2009) CD20-targeted tetrameric interferon-alpha, a novel and potent immunocytokine for the therapy of B-cell lymphomas. Blood 114: 3864-3871.
38. Rossi EA, Rossi DL, Cardillo TM, Stein R, Goldenberg DM, et al. (2011) Preclinical studies on targeted delivery of multiple IFNalpha2b to HLA-DR in diverse hematologic cancers. Blood 118: 1877-1884.
39. Rossi DL, Rossi EA, Goldenberg DM, Chang CH, (2011) A new mammalian host cell with enhanced survival enables completely serum-free development of high-level protein production cell lines. Biotechnol Prog 27: 766-775.
40. Okano J, Gaslightwala I, Birnbaum MJ, Rustgi AK, Nakagawa H, (2000) Akt/protein kinase B isoforms are differentially regulated by epidermal growth factor stimulation. J Biol Chem 275: 30934-30942.
41. Blight KJ. and Norgard EA (2006) HCV Replicon Systems. In: Tan SL, editor. Hepatitis C Viruses: Genomes and Molecular Biology. Norfolk (UK): Horizon Bioscience. 311-351.
42. Miyamoto M, Kato T, Date T, Mizokami M, Wakita T, (2006) Comparison between Subgenomic Replicons of Hepatitis C Virus Genotypes 2a (JFH-1) and 1b (Con1 NK5.1). Intervirology 49: 37-43.
43. Lavoie TB, Kalie E, Crisafulli-Cabatu S, Abramovich R, DiGioia G, et al. (2011) Binding and activity of all human alpha interferon subtypes. Cytokine 56: 282-289.
44. Byrnes-Blake KA, Pederson S, Klucher KM, Anderson-Haley M, Miller DM, et al. (2012) Pharmacokinetics and pharmacodynamics of pegylated interferon lambda-1 in cynomolgus monkeys. J Interferon Cytokine Res 32: 198-206.
45. Ank N, West H, Paludan SR, (2006) IFN-lambda: novel antiviral cytokines. J Interferon Cytokine Res 26: 373-379.
46. Abushahba W, Balan M, Castaneda I, Yuan Y, Reuhl K, et al. (2010) Antitumor activity of type I and type III interferons in BNL hepatoma model. Cancer Immunol Immunother 59: 1059-1071.
47. Lasfar A, Lewis-Antes A, Smirnov SV, Anantha S, Abushahba W, et al. (2006) Characterization of the mouse IFN-lambda ligand-receptor system: IFN-lambdas exhibit antitumor activity against B16 melanoma. Cancer Res 66: 4468-4477.
48. Pardoll D, Drake C, (2012) Immunotherapy earns its spot in the ranks of cancer therapy. J Exp Med 209: 201-209.
49. Grace MJ, Lee S, Bradshaw S, Chapman J, Spond J, et al. (2005) Site of pegylation and polyethylene glycol molecule size attenuate interferon-alpha antiviral and antiproliferative activities through the JAK/STAT signaling pathway. J Biol Chem 280: 6327-6336.